Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

MKSAP 19 > Pulmonary and Critical Care Medicine > Flashcards

Pulmonary and Critical Care Medicine Flashcards

1
Q

Diagnostic Imaging pleural effusion

A
  1. CXR should be performed as the first test

2.U/S is a helpful addition to CXR for identification of small effusions

3.CT with contrast include the ability to detect small amounts of pleural fluid; the assessment of coexisting intrathoracic abnormalities, such as pulmonary masses and malignant pleural disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

multiseptated (loculated) pleural effusion is ……..

A

exudate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Indications for Diagnostic Thoracentesis

A

new effusion of unclear etiology and > 1 cm of fluid thickness

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Pleural fluid triglycerides, support the diagnosis of chylothorax if it’s

A

> 110 mg/dL (1.24 mmol/L)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Complicated parapneumonic effusions treatment

A
  • drainage.

Options for drainage include early surgical intervention via video-assisted thoracoscopic surgery and chest tube drainage with or without the combined use of intrapleural fibrinolytics and a mucolytic agent (deoxyribonuclease, or DNase).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Malignant Pleural Effusion treatment

A

Repeat therapeutic thoracentesis is appropriate for patients with poor prognosis (less than 3 months) and slow reaccumulation of fluid.

Patients with rapid reaccumulation of fluid and dyspnea should be offered more definitive management. Indwelling pleural catheters with intermittent outpatient drainage

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Nonmalignant Pleural Effusion treatment

A

If diagnostic uncertainty persists, additional evaluation with imaging (chest CT with contrast) and possible thoracoscopy should be considered.

Options for management include tunneled pleural catheters, pleurodesis, or both after careful discussion with a multidisciplinary team.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

considered a large pneumothorax if

A

If the lung margin is greater than 2 cm away from the chest wall at the level of the hilum

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Management of Pneumothorax
if <2 cm on chest radiograph, minimal symptoms

A

Needle aspiration or admit to hospital for observation and supplemental oxygen (PSP may be managed as an outpatient if good access to medical care)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Management of Pneumothorax
if >2 cm on chest radiograph, breathlessness, and chest pain

A

Insertion of a small-bore (<14 Fr) thoracostomy tube with connection to a high-volume low-pressure suction system

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Management of Pneumothorax
if Cardiovascular compromise (hypotension, increasing breathlessness) regardless of size

A

Emergent needle decompression followed by thoracostomy tube insertion

Note: If persistent air leak (>48 hours), refer to an interventional pulmonologist or thoracic surgeon

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Intervention to prevent recurrence of pneumothorax.

A

chemical and mechanical pleurodesis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

in pneumothorax
1. Air travel should be avoided

2.scuba diving

A
  1. until complete resolution
  2. not recommended unless definitive therapy such as surgical pleurectomy has been applied.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Pleural-fluid LDH level in exudative pleural effusion

A

> 2/3 upper limit of normal for serum LDH

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Diagnoses suggested by elevated pleural fluid amylase

A

Pancreatitis, esophageal rupture

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Pulmonary Hypertension definition

A

resting mPAP of 20 mm Hg or greater

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Classification of Pulmonary Hypertension

A
  1. PH (includes idiopathic and heritable disease, disease associated with use of drugs or toxins, connective tissue diseases, HIV infection, congenital heart disease, schistosomiasis, and portal hypertension; also includes vasoresponsive PAH and PAH attributable to pulmonary venoocclusive disease or pulmonary capillary hemangiomatosis)

2.PH due to left-sided heart disease

3.PH due to lung diseases or hypoxia

4.Chronic thromboembolic pulmonary hypertension and other pulmonary artery obstructions

5.PH with unclear or multifactorial causes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Evaluation of Suspected Pulmonary Hypertension

A
  1. ECHO (should not be used to confirm a PH diagnosis because is often inaccurate)

2.PFT, HRCT, Sleep Study

3.serologic tests for underlying connective tissue disease, hepatitis, and HIV are advised

  1. V/Q scan to evaluate for chronic thromboembolic PH

5.Right heart catheterization is essential to confirm a diagnosis of PH

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

When V/Q scan suggests chronic thrombus, additional imaging to evaluate the extent of CTEPH is indicated.

A

Digital subtraction angiography

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

current guidelines recommend that patients with CTEPH undergo screening for

A

thrombophilia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Chronic Thromboembolic Pulmonary Hypertension (Group 4)
treatment

A

Anticoagulation and consideration of thromboendarterectomy are indicated for CTEPH.

Lifelong anticoagulant therapy is indicated in all patients to help prevent further thromboembolism.

In inoperable patients and those who have persistent PH after thromboendarterectomy, balloon pulmonary angioplasty or medical therapy (Riociguat) should be considered.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

apnea-hypopnea index : mid

A

5-14

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

apnea-hypopnea index moderate

A

15-30

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

apnea-hypopnea index severe

A

> 30

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

The most important risk factor for obstructive sleep apnea is

A

obesity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Overnight pulse oximetry for

A

asymptomatic with a low pretest probability, normal overnight oximetry might support the decision to avoid further testing.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

OSA treatment

A

1.bariatric surgeon should be considered for patients with BMI ≥35 who have not benefited from or are intolerant of positive airway pressure therapy.
2. CPAP or BIPAP in hypoventilation syndrome

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

On polysomnography, absence of respiratory effort associated with loss of airflow for at least 10 seconds.

A

central apnea

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

Initial management of CSA

A
  1. should target modifiable risk factors (reduction or elimination of opioids improves CSA &Medical optimization of heart failure)
  2. CPAP may occasionally be useful, especially in patients with overlapping OSA
  3. oxygen during sleep may be indicated for who have hypoxia during sleep, as well as for those who cannot use or tolerate CPAP
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

CPAP treatment alternative for mild/moderate OSA

A

Oral appliance

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

Diagnosis suggested by nocturnal absence of respiratory effort and airflow

A

CSA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

DLCO
Mild

A

> 60

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

DLCO
moderate

A

40-60

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

DLCO
severe

A

< 40

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

An increase from baseline in FEV1, FVC, or both of at least …………relative to the predicted value indicates a positive bronchodilator response

A

10%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

in obstructive pattern FEV1/FVC ratio

A

< 0.70

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

TLC is normal or even increased in

A

pure obstructive disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

If FEV1 or FVC is reduced and the FEV1/FVC ratio is 0.70 or greater

A

restrictive pattern may be interpreted, but measurement of TLC is needed to confirm this.

If TLC is less than 80% of predicted (or the lower limit of normal), a restrictive pattern is present.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

coexisting obstructive and restrictive pulmonary disorders
FEV1/FVC ratio&raquo_space;
TLC&raquo_space;

A

low FEV1/FVC ratio (obstructive) and a low TLC (restrictive) are both present

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
40
Q

In cases of suspected inaccurate pulse oximetry by finger probe, changing to

A

an earlobe probe or forehead probe is indicated.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
41
Q

Positive bronchial challenge test result

A

FEV1 > 0.2 ml or 12 %

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
42
Q

Allergic Bronchopulmonary Aspergillosis
diagnosis

A

1.presence of asthma
2.elevated IgE levels
3.positive skin tests to Aspergillus antigens
4.increased Aspergillus-specific IgE and IgG levels
5.either central bronchiectasis or infiltrates.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
43
Q

Allergic Bronchopulmonary Aspergillosis
treatment

A

Management is aimed at
1.suppressing the enhanced immunologic response with systemic glucocorticoids

2.reducing the fungal antigenic burden with antifungal agents

44
Q

target interleukin-5 (IL-5)

A
  1. mepo (lizumab)
  2. res (lizumab)
  3. benra (lizumab)
45
Q

anti-IgE biologic

A

omalizumab

46
Q

inhibitor of IL-4 and IL-13

A

dupilumab

47
Q

BA management in Step 1

A

SABA as needed

Or ICS & SABA as needed

48
Q

BA management in Step 2

A

Daily low dose ICS & SABA as needed

Or

ICS & SABA as needed

49
Q

BA management in Step 3

A

Daily & as needed combination low dose ICS- formoterol

50
Q

BA management in Step 4

A

Daily & as needed combination medium dose ICS - formoterol

51
Q

BA management in Step 5

A

Daily medium to high dose ICS- LABA + LAMA & SABA as needed

52
Q

BA management in Step 6

A

Daily high dose ICS - LABA + oral steroid + SABA as needed
Consider add-on
Anti IgE
Anti IL5,
Anti IL4/ IL13

53
Q

Cystic Fibrosis is

A

autosomal recessive
results in abnormally thick secretions that are difficult to clear.

54
Q

the initial test for CF is

A

Sweat chloride testing

Abnormal results on repeat testing are diagnostic of CF

Genetic testing confirms the diagnosis and helps with prognosis.

55
Q

treatment of CF

A

airway clearance
antibiotic therapy
nutritional support
psychosocial support.

56
Q

Bronchiectasis is diagnosed by

A

HRCT.
Diagnostic criteria include an airway diameter that is greater than that of its accompanying vessel and lack of distal airway tapering

57
Q

treatment of bronchiectasis focuses on

A

clearing the airway
treating infections
preventing exacerbations
Patients should also be encouraged to exercise, which can improve airway clearance and symptoms.

Surgical resection should be considered in patients who have localized disease with persistent symptoms despite therapy.

58
Q

Treatment of Exacerbations of bronchiectasis

A

Therapy is guided by routine sputum and AFB culture results.

Empiric antibiotic therapy is recommended and may be based on previous culture data until the results of the current sputum culture become available.

If previous data are not available, a fluoroquinolone can be started to ensure Pseudomonas coverage until sputum culture results are available.

59
Q

The 2023 guidelines recommend adding inhaled glucocorticoids in COPD if:

A
  • if eosinophil count exceeds 300/uL,
  • if exacerbations are uncontrolled and the eosinophil count is > 100/uL
  • if the patient has significant asthmatic features along with COPD.
60
Q

selective phosphodiesterase-4 inhibitor that is used to reduce the frequency of exacerbations in patients with severe COPD who have primarily symptoms of chronic bronchitis.

A

Roflumilast

61
Q

Indications for long-term oxygen therapy

A
  1. Hypoxia: PaO2 ≤55 mmHg (7.32 kPa) or SaO2 ≤88 %
  2. In the presence of cor pulmonale
    PaO2 ≤59 mmHg (7.85 kPa) or SaO2 ≤89 %
    Hematocrit > 55 %
    Clinical evidence of right HF
62
Q

Ideal patients for lung volume reduction therapy

A

1.upper-lobe-predominant emphysema,

2.FEV1 and DLCO of 20% of predicted or higher, and

3.low exercise tolerance after completion of pulmonary rehabilitation.

63
Q

Antibiotic class for severe COPD with frequent exacerbations

A

Macrolide

64
Q

LÖfgren syndrome

A

1.Acute

  1. Erythema nodosum
  2. Arthritis
  3. Hilar adenopathy
65
Q

Heerfordt Waldenström

A
  1. Subacute to chronic
  2. Fever
  3. Parotid enlargement
  4. Uveitis
  5. Facial palsy
66
Q

Asbestos exposure, progressive Dyspnea, pleurtic chest pain , bloody pleural effusion

A

Mesothelioma

67
Q

Patient with silicosis are at risk concurrent…….infection

A

TB

68
Q
  1. Asbestosis involves the ……. Lung
  2. Silicosis involves the ….. lung
A
  1. Lower
  2. Upper
69
Q

recommend serologic testing to exclude CTD-associated DPLD.

A

Routine testing with
CRP,
ESR,
ANA,
RF, ACCP
myositis panel.

70
Q

smoking-related DPLDs, the primary management is

A

smoking cessation.

Glucocorticoids may be considered with severe disease or in those with refractory symptoms.

71
Q

treatment of Hypersensitivity Pneumonitis

A

Removal of exposure to the offending antigen

Glucocorticoids and sometimes other immunosuppressants are often used for those with more severe symptoms.

72
Q

Management of patients with IPF

A

oxygen supplementation for hypoxemia and antifibrotic therapies
- nintedanib
-pirfenidone

73
Q

treatment of Cryptogenic Organizing Pneumonia

A

Patients with COP respond well to glucocorticoid therapy. Relapses of COP with tapering of glucocorticoids are common

74
Q

treatment of Acute Interstitial Pneumonia

A

Management includes ventilatory support and critical care, as it does for patients with ARDS.

often treated with high-dose glucocorticoid

75
Q

Single Pulmonary Nodule Follow-Up <6 mm

A

low risk no f/u
high risk at 12 months

76
Q

Single Pulmonary Nodule Follow-Up 6 - 8 mm

A

6-12 months then 18-24 moths

77
Q

Single Pulmonary Nodule Follow-Up > 8 mm

A

at 3 months with
1. CT or

  1. PET or
  2. tissue sampling
78
Q

Solitary Subsolid Lung Nodule Follow-Up Pure ground glass & Part solid nodule

A

if < 6 mm no f/u

Pure ground glass ≥6 mm CT at 6-12 months to confirm persistence, then CT every 2 years until 5 years

Part solid nodule ≥6 mm CT at 3-6 months to confirm persistence; if unchanged and solid component remains <6 mm, annual CT should be performed for 5 years

79
Q

types of lung cancer

A

1.small cell cancer ( smoker,cerntral,SIADH)

2.non-small cell cancer
-adenocarcinoma (peripheral , non smoker)
-large cell carcinoma (peripheral )
-squamous cell carcinoma ( smoker,cerntral)

80
Q

Annual lung cancer screening should be performed in

A

patients aged 50 through 80 years who have no symptoms of lung cancer, have at least a 20-pack-year smoking history, and are current smokers or have quit within the last 15 years.

81
Q

Cessation of lung cancer screening should be considered in

A

1.those who have not smoked in 15 years,

2.those with limited life expectancy, and

3.those who would not be candidates for or would not be willing to undergo surgery.

82
Q

Diagnosis suggested by headache, nausea, disturbed sleep at altitude

A

Acute mountain sickness

83
Q

Treatment for high-altitude cerebral edema

A

Dexamethasone, oxygen, descent

84
Q

Drug treatments for high-altitude pulmonary edema

A

Nifedipine, PDE-5 inhibitor

85
Q

Possible complication in air travel for patients with asthma or COPD

A

Pneumothorax

86
Q

Oxygen saturation level requiring supplemental O2 during air travel

A

<92%

87
Q

Test to determine need for supplemental O2 during air travel

A

Hypoxia altitude simulation testing

88
Q

Enteral nutrition should start within

A

24 to 48 hours of admission.

89
Q

Alleviate hypoxemia by MV

A

Increasing FIO2

Increasing PEEP

90
Q

Improve respiratory alkalosis BY MV

( Hypocapnia )

A

Decreasing respiratory rate

Decreasing tidal volume

91
Q

Improve respiratory acidosis BY MV

( Hypercapnia)

A

Increasing respiratory rate

Increasing tidal volume

92
Q

Berlin definition of ARDS

A
  1. Symptoms must have begun within 1 week of a known clinical insult
  2. Bilateral opacities consistent with pulmonary edema on CXR
  3. Respiratory failure ( not explained by HF or fluid overload)
  4. Arterial pO2/FiO2 < 300 with PEEP at least 5
93
Q

Severity of ARDS
PaO2/FiO2 ration on MV settings PEEP >= 5

A

Mild 201- 300

Moderate 101-200

Severe =< 100

94
Q

ARDS VENTILATOR SETTING

A

FiO2 100 % and lower < 60 % ASAP

TV 6-8 ml /kg

PEEP start at 5 and titrate to plateau pressure =< 30 cmH2O

95
Q

CO low
PCWP high
SVR high
Which type of shock

A

Cardiac shock

96
Q

CO low
PCWP low
SVR high
Which type of shock

A

Hypovolemic shock

97
Q

CO high
PCWP low
SVR low
Which type of shock

A

Distributive shock

98
Q

Indication of prone position in ARDS

A

If pO2/FiO2 ratio < 150 and FiO2 at least 60

At least 12-16 hours a day

99
Q

Therapeutic treatment of severe refractory respiratory failure resulting from ARDS

A

ECMO

100
Q

Diagnosis of Hereditary angioedema by

A
  1. Quantitive & functional levels of C1 esterase inhibitor and
  2. C4 complement level
101
Q

Treatment of malignant hyperthermia

A
  1. DC the triggering agent

2.Active cooling

3.Muscle relaxant dantrolene every 5 to 10 minutes until muscle rigidity and hyperthermia resolve.

102
Q

TREATMENT OF Serotonin syndrome

A

removing the offending agent and supportive care.
Cyproheptadine is sometimes used if benzodiazepines fail to control symptoms.

103
Q

TREATMNET OF Neuroleptic malignant syndrome

A
  1. stopping the triggering agent (or reinstating the withdrawn dopaminergic agent)
  2. active cooling
  3. supportive care including IV fluid administration.
  4. Evidence for pharmacotherapy is anecdotal, but options include benzodiazepines, dantrolene, and bromocriptine.

Neuroleptic medications can be reintroduced after a waiting period of at least 2 weeks, usually at lower dose, with care to avoid dehydration and concomitant administration with lithium.

104
Q

Neuroleptic Malignant Syndrome & Serotonin Syndrome

A

Neuroleptic Malignant Syndrome:
tetrad of fever, mental status changes, dysautonomia AND muscle rigidity.

Serotonin Syndrome:
fever, mental status changes, dysautonomia, hyperreflexia, and other muscle abnormalities.

105
Q

Patients with high levels of carboxyhemoglobin (25% and greater) and evidence of organ ischemia should be treated with

A

hyperbaric oxygen if possible.

106
Q

Heat stroke treatment

A
  1. Evaporative cooling ( water mist & fans )
  2. Immersion in ice water for only young patients when they remain severely symptomatic despite evaporative cooling.
  • acetaminophen is not effective for heat stroke
107
Q

Diagnose glucocorticoid-responsive asthma with

A

fractional exhaled nitric oxide testing

MKSAP 19 (12 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions